Article
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Molecular cancer - 18 Jan 2021
Wu Shaocong, Luo Min, To Kenneth K W, Zhang Jianye, Su Chaoyue, Zhang Hong, An Sainan, Wang Fang, Chen Da, Fu Liwu
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The underlying mechanisms of osimertinib resistance remain largely unexplored. METHODS: Exosomes isolation was performed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.